{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:14:17Z","timestamp":1772165657657,"version":"3.50.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,21]],"date-time":"2021-01-21T00:00:00Z","timestamp":1611187200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,1,21]],"date-time":"2021-01-21T00:00:00Z","timestamp":1611187200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"publisher","award":["015\/0306"],"award-info":[{"award-number":["015\/0306"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Ending the global tuberculosis (TB) epidemic requires a focus on treating individuals with latent TB infection (LTBI) to prevent future cases. Promising trials of shorter regimens have shown them to be effective as preventative TB treatment, however there is a paucity of data on self-administered treatment completion rates. This pilot trial assessed treatment completion, adherence, safety and the feasibility of treating LTBI in the UK using a weekly rifapentine and isoniazid regimen versus daily rifampicin and isoniazid, both self-administered for 12 weeks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>An open label, randomised, multi-site pilot trial was conducted in London, UK, between March 2015 and January 2017. Adults between 16 and 65\u2009years with LTBI at two TB clinics who were eligible for and agreed to preventative therapy were consented and randomised 1:1 to receive either a weekly combination of rifapentine\/isoniazid (\u2018intervention\u2019) or a daily combination of rifampicin\/isoniazid (\u2018standard\u2019), with both regimens taken for twelve weeks; treatment was self-administered in both arms. The primary outcome, completion of treatment, was self-reported, defined as taking more than 90% of prescribed doses and corroborated by pill counts and urine testing. Adverse events were recorded.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Fifty-two patients were successfully enrolled. In the intervention arm 21 of 27 patients completed treatment (77.8, 95% confidence interval [CI] 57.7\u201391.4), compared with 19 of 25 (76.0%, CI 54.9\u201390.6) in the standard of care arm. There was a similar adverse effect profile between the two arms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this pilot trial, treatment completion was comparable between the weekly rifapentine\/isoniazid and the daily rifampicin\/isoniazid regimens. Additionally, the adverse event profile was similar between the two arms. We conclude that it is safe and feasible to undertake a fully powered trial to determine whether self-administered weekly treatment is superior\/non-inferior compared to current treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      The trial was funded by the NIHR, UK and registered with ISRCTN (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.isrctn.com\/ISRCTN04379941\">26\/02\/2013-No.04379941<\/jats:ext-link>\n                      ).\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-021-05766-9","type":"journal-article","created":{"date-parts":[[2021,1,21]],"date-time":"2021-01-21T02:02:57Z","timestamp":1611194577000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["An open label, randomised controlled trial of rifapentine versus rifampicin based short course regimens for the treatment of latent tuberculosis in England: the HALT LTBI pilot study"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2411-0477","authenticated-orcid":false,"given":"J.","family":"Surey","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. R.","family":"Stagg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T. A.","family":"Yates","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Lipman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. J.","family":"White","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Charlett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Gosce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. X.","family":"Rangaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Francis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Hack","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Kunst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Abubakar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,1,21]]},"reference":[{"key":"5766_CR1","unstructured":"WHO. World Health Organisation: Global tuberculosis report 2018. Geneva: World Health Organization. p. 2018."},{"key":"5766_CR2","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12916-016-0595-5","volume":"14","author":"M Pareek","year":"2016","unstructured":"Pareek M, Greenaway C, Noori T, Munoz J, Zenner D. The impact of migration on tuberculosis epidemiology and control in high-income countries: a review. BMC Med. 2016;14:48.","journal-title":"BMC Med"},{"issue":"6","key":"5766_CR3","doi-asserted-by":"publisher","first-page":"624","DOI":"10.5588\/ijtld.16.0845","volume":"21","author":"K L\u00f6nnroth","year":"2017","unstructured":"L\u00f6nnroth K, Mor Z, Erkens C, Bruchfeld J, Nathavitharana RR, van der Werf MJ, et al. Tuberculosis in migrants in low-incidence countries: epidemiology and intervention entry points. Int J Tuberc Lung Dis. 2017;21(6):624\u201336.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"23","key":"5766_CR4","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1056\/NEJMoa1104875","volume":"365","author":"TR Sterling","year":"2011","unstructured":"Sterling TR, Villarino ME, Borisov AS, Shang N, Gordin F, Bliven-Sizemore E, et al. Three months of Rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med. 2011;365(23):2155\u201366.","journal-title":"N Engl J Med"},{"issue":"4","key":"5766_CR5","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/S1081-1206(10)60532-7","volume":"103","author":"JL Cohen","year":"2009","unstructured":"Cohen JL, Mann DM, Wisnivesky JP, Horne R, Leventhal H, Musumeci-Szab\u00f3 TJ, et al. Assessing the validity of self-reported medication adherence among inner-city asthmatic adults: the medication adherence report scale for asthma. Ann Allergy Asthma Immunol. 2009;103(4):325\u201331.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"6","key":"5766_CR6","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1080\/08870446.2010.490585","volume":"26","author":"PA Mora","year":"2011","unstructured":"Mora PA, Berkowitz A, Contrada RJ, Wisnivesky J, Horne R, Leventhal H, et al. Factor structure and longitudinal invariance of the medical adherence report scale-asthma. Psychol Health. 2011;26(6):713\u201327.","journal-title":"Psychol Health"},{"key":"5766_CR7","unstructured":"U.S. Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases, AIDS Do. Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events. Corrected Version 2.1 ed. 2017."},{"issue":"10","key":"5766_CR8","doi-asserted-by":"publisher","first-page":"689","DOI":"10.7326\/M17-1150","volume":"167","author":"R Belknap","year":"2017","unstructured":"Belknap R, Holland D, Feng P-J, Millet J-P, Cayl\u00e0 JA, Martinson NA, et al. Self-administered versus directly observed once-weekly isoniazid and Rifapentine treatment of latent tuberculosis infection: a randomized trial. Ann Intern Med. 2017;167(10):689\u201397.","journal-title":"Ann Intern Med"},{"issue":"12","key":"5766_CR9","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1111\/imj.13601","volume":"47","author":"JT Denholm","year":"2017","unstructured":"Denholm JT, McBryde ES, Eisen D, Street A, Matchett E, Chen C, et al. SIRCLE: a randomised controlled cost comparison of self-administered short-course isoniazid and rifapentine for cost-effective latent tuberculosis eradication. Intern Med J. 2017;47(12):1433\u20136.","journal-title":"Intern Med J"},{"issue":"1","key":"5766_CR10","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1186\/s12879-018-3468-z","volume":"18","author":"YL Schein","year":"2018","unstructured":"Schein YL, Madebo T, Andersen HE, Arnesen TM, Dyrhol-Riise AM, Tveiten H, et al. Treatment completion for latent tuberculosis infection in Norway: a prospective cohort study. BMC Infect Dis. 2018;18(1):587.","journal-title":"BMC Infect Dis"},{"key":"5766_CR11","unstructured":"NIHR. National Institute for Health Research Award: Research to Improve the Detection and Treatment of Latent Tuberculosis Infection (RID-TB) 2018 [Available from: https:\/\/fundingawards.nihr.ac.uk\/award\/RP-PG-0217-20009."},{"key":"5766_CR12","doi-asserted-by":"crossref","unstructured":"Stagg HR, Lewis JJ, Liu X, Huan S, Jiang S, Chin DP, et al. Temporal Factors and Missed Doses of Tuberculosis Treatment: A Causal Associations Approach to Analyses of Digital Adherence Data. Annals of the American Thoracic Society. 2019.","DOI":"10.1513\/AnnalsATS.201905-394OC"},{"issue":"9","key":"5766_CR13","doi-asserted-by":"publisher","first-page":"e1001876","DOI":"10.1371\/journal.pmed.1001876","volume":"12","author":"X Liu","year":"2015","unstructured":"Liu X, Lewis JJ, Zhang H, Lu W, Zhang S, Zheng G, et al. Effectiveness of Electronic Reminders to Improve Medication Adherence in Tuberculosis Patients: A Cluster-Randomised Trial. PLoS Med. 2015;12(9):e1001876.","journal-title":"PLoS Med"},{"issue":"4","key":"5766_CR14","first-page":"555","volume":"60","author":"International Union Against Tuberculosis Committee on P","year":"1982","unstructured":"International Union Against Tuberculosis Committee on P. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. International Union Against Tuberculosis Committee on Prophylaxis. Bull World Health Organ. 1982;60(4):555\u201364.","journal-title":"Bull World Health Organ"},{"issue":"12","key":"5766_CR15","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1002\/pds.4334","volume":"26","author":"WF Gellad","year":"2017","unstructured":"Gellad WF, Thorpe CT, Steiner JF, Voils CI. The myths of medication adherence. Pharmacoepidemiol Drug Saf. 2017;26(12):1437\u201341.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"11","key":"5766_CR16","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1056\/NEJMoa1806808","volume":"380","author":"S Swindells","year":"2019","unstructured":"Swindells S, Ramchandani R, Gupta A, Benson CA, Leon-Cruz J, Mwelase N, et al. One month of Rifapentine plus isoniazid to prevent HIV-related tuberculosis. N Engl J Med. 2019;380(11):1001\u201311.","journal-title":"N Engl J Med"},{"issue":"5","key":"5766_CR17","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1164\/rccm.201908-1606OC","volume":"201","author":"JE Stout","year":"2020","unstructured":"Stout JE, Turner NA, Belknap RW, Horsburgh CR, Sterling TR, Phillips PPJ. Optimizing the Design of Latent Tuberculosis Treatment Trials: Insights from Mathematical Modeling. Am J Respir Crit Care Med. 2020;201(5):598\u2013605.","journal-title":"Am J Respir Crit Care Med"},{"key":"5766_CR18","volume-title":"Rapid Communication on forthcoming changes to the programmatic management of tuberculosis preventive treatment","author":"WHO","year":"2020","unstructured":"WHO. Rapid Communication on forthcoming changes to the programmatic management of tuberculosis preventive treatment. Geneva: World Health Organization; 2020."}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-021-05766-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12879-021-05766-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-021-05766-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,21]],"date-time":"2021-01-21T02:05:03Z","timestamp":1611194703000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-021-05766-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,21]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["5766"],"URL":"https:\/\/doi.org\/10.1186\/s12879-021-05766-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-102558\/v1","asserted-by":"object"}]},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,21]]},"assertion":[{"value":"15 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethical approval was obtained from the UK NHS Research Ethics Committee (Reference Number: 13\/LO\/1666). Written informed consent was obtained from all study participants prior to any study interventions being carried out.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"90"}}